# A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia

Study · id `cardio:ct-nct06568471` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06568471](<https://clinicaltrials.gov/study/NCT06568471>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06568471

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 210 participants.

## Technical summary

Registry record NCT06568471. Randomized; triple masking; primary purpose treatment. Start 2024-11-16 (actual); primary completion 2026-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 210 participants (planned count; ClinicalTrials.gov record NCT06568471, source copy `cardio:ctgov-nct06568471-2025-02-06`, retrieved 2026-10-31)
- Started: 2024-11-16 (actual) (ClinicalTrials.gov record NCT06568471, source copy `cardio:ctgov-nct06568471-2025-02-06`, retrieved 2026-10-31)
- Primary completion: 2026-02 (anticipated) (ClinicalTrials.gov record NCT06568471, source copy `cardio:ctgov-nct06568471-2025-02-06`, retrieved 2026-10-31)
- Completion: 2026-05 (anticipated) (ClinicalTrials.gov record NCT06568471, source copy `cardio:ctgov-nct06568471-2025-02-06`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT06568471, source copy `cardio:ctgov-nct06568471-2025-02-06`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06568471-2025-02-06`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
- Condition: Hypercholesterolemia
- Condition: Dyslipidemias
- Condition: Primary Hypercholesterolemia
- Condition: Heterozygous Familial Hypercholesterolemia
- Condition: Hyperlipidemia; Mixed
- Condition: Metabolic Disease
- Condition: ASCVD
- Intervention (Drug): Lerodalcibep
- Intervention (Drug): matching placebo
- Lead sponsor: Hasten Biopharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Familial hypercholesterolemia (`cardio:familial-hypercholesterolemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)

## Provenance

Content hash: add151570a74c68f93755845122c5c92cd69b0683bdf4d7b86bf5ddef390ae45
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
